ACQT 1127
Alternative Names: ACQT-1127; RLBN-1127Latest Information Update: 28 Oct 2022
At a glance
- Originator Acquist Therapeutics
- Class Antigouts; Hepatoprotectants; Small molecules
- Mechanism of Action Enzyme inhibitors; SLC22A12 protein inhibitors; Xanthine oxidase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Gout; Non-alcoholic steatohepatitis
Most Recent Events
- 28 Oct 2022 No recent reports of development identified for preclinical development in Gout in USA (PO)
- 28 Oct 2022 No recent reports of development identified for preclinical development in Non-alcoholic-steatohepatitis in USA (PO)
- 27 May 2020 Acquist Therapeutics announces intention to submit IND to the US FDA for non-alcoholic steatohepatitis (NASH) and gout to start clinical trials